Additionally, baseline medical therapy for the treatment and prevention of atherosclerosis was more optimal in the LoDoCo2 cohort, with 96.6% (vs. 76.1%) taking a lipid-lowering drug, 99.7% (vs. 14.4%, excluding over-the-counter aspirin) taking an antiplatelet, and 71.7% (vs. 63.7%) taking an inhibitor of the renin–angiotensin system. Here, REN is linked to atherosclerosis.